Glaukos Corporation (GKOS) jumps on record Q3 results
Glaukos Corporation (GKOS) jumps after reporting record third-quarter sales, raising 2026 guidance and unveiling a preliminary $1 billion 2027 sales target. The stronger growth outlook, margin expansion and analyst target hikes helped push the stock above its prior close and 52-week high in after-hours trading.
Glaukos Corporation (GKOS) jumped 15.7% in after-hours trading after reporting record third-quarter revenue, stronger margins and a raised 2026 outlook. Management also introduced a preliminary $1 billion 2027 sales target, signaling a much bigger long-term growth runway for investors. The move reflects a meaningful reset in the stock’s valuation, though regular-session trading will determine whether the breakout holds.
Glaukos Corporation (GKOS) Jumps After Strong Q3 Results
Glaukos Corporation (GKOS) jumps 15.75% in after-hours trading to $210 after its October 28 third-quarter report delivered record sales, higher 2026 guidance and a preliminary $1B 2027 sales target. The move lifts the stock above its prior $181.43 close and its $191.62 52-week high; because this is an extended-hours print, regular-session trading will confirm whether the gain holds.
Key Takeaways
GKOS traded at $210 after hours, up 15.75% from the prior close and above its $191.62 52-week high.
The primary catalyst was Q3 revenue of $211.03M, up 58% year over year and 24.99% above the $168.84M consensus estimate.
Glaukos raised 2026 net sales guidance to $775M-$785M and introduced preliminary 2027 guidance of $1B.
The stronger growth outlook supports a higher valuation, but the $10.70B market cap also makes execution important after such a sharp repricing.
The clearest catalyst is Glaukos's October 28 third-quarter earnings announcement. , an increase of 58% from the same quarter last year.
That result changed the near-term growth narrative in two important ways. First, revenue growth accelerated across key operating areas. U.S. glaucoma sales reached $118.6M, up 47% year over year, while corneal health sales reached $59.0M, up 154%. Second, Glaukos raised full-year 2026 sales guidance from $680M-$700M to $775M-$785M.
The company also gave investors a preliminary 2027 sales target of $1B. For a medical-device business with a $10.70B market cap, that figure adds a longer runway to the story. It also explains why the stock jumped beyond its prior trading range instead of reacting to the quarter as a routine earnings beat.
Analyst actions reinforced the repricing on October 29. Piper Sandler raised its price target to $240 from $195, Needham set a $251 target, Mizuho set $225, and Truist raised its target to $255. Those updates did not create the original catalyst, but they added institutional support after the results.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Glaukos's Q3 Financial Results Reset the Growth Case
The quarter offered more than top-line growth. Glaukos reported an approximately 85% gross margin, compared with about 78% in the prior-year quarter. Reported net income reached $2.0M, while non-GAAP net income was $28.5M.
That combination matters because higher sales and wider gross margins give the business more room to absorb research, sales and commercialization costs. The company also ended the quarter with $339.8M in cash and investments, up $50.5M from the second quarter. The balance sheet therefore adds financial flexibility as Glaukos expands its product portfolio.
The earnings picture was also stronger than the headline loss history shown in the stock data. Zacks reported adjusted Q3 earnings of $0.47 per share against a consensus estimate for a $0.12 loss. However, the most durable part of the investment case is the combination of $211.03M in revenue, higher guidance and the $1B preliminary 2027 target.
Valuation remains the balancing factor. A $10.70B market cap against 2026 sales guidance of $775M-$785M places a high value on continued growth. Therefore, the stock now needs strong execution across several quarters, not just one impressive report, to justify the new price level.
Why Glaukos's Ophthalmology Platform Supports the Premium
Glaukos has built a broader ophthalmology platform rather than relying on one product. The company pioneered Micro-Invasive Glaucoma Surgery and commercially launched its first MIGS device in 2012. Its portfolio now includes iStent products, iDose TR for glaucoma, Epioxa for corneal health and an emerging retinal disease program.
The latest results show why that platform matters. Glaucoma generated record U.S. sales of $118.6M, while corneal health grew to $59.0M. Glaukos has identified iDose TR and Epioxa as two transformational growth drivers, giving investors separate product paths inside the same company.
The October 8 agreement with RevOpsis Therapeutics adds another layer. Glaukos received an exclusive license to develop and commercialize RO-104, a tri-specific biologic for retinal diseases, along with access to the RevMod platform for up to four additional biologic candidates. That deal did not trigger the current move, but it expands the long-term addressable market beyond glaucoma and corneal disorders.
This mix of established devices, newer drug-device therapies and pipeline assets helps explain the market's enthusiasm. Still, a strong competitive position does not remove execution risk. Physician adoption, product launches and clinical development must continue to support the $775M-$785M 2026 outlook and the $1B 2027 ambition.
How Investors Can Approach GKOS After the Earnings Repricing
The fundamental upgrade is real: Q3 sales rose 58%, gross margin expanded to about 85%, 2026 guidance increased, and management introduced a $1B 2027 sales target. Those facts support a higher valuation framework for GKOS than the one in place before October 28.
At the same time, a 15.75% after-hours gain creates a poor setting for emotional buying. A disciplined approach is to use the $181.43 regular-session close and the $191.62 52-week high as reference levels, then judge whether regular-session trading establishes support above those levels. For existing holders, the same prices provide concrete markers for assessing whether the breakout has conviction.
GKOS is gaining because investors received a specific earnings and guidance reset, not because of vague sector excitement. If the company converts its record sales, margin expansion and 2027 target into sustained results, the after-hours jump marks a meaningful shift in the growth story. Regular-session price action will determine whether the market accepts that new valuation.
GKOS is up because Glaukos reported record Q3 sales of $211.0 million, far above expectations, and raised its 2026 guidance. The company also introduced a preliminary $1 billion 2027 sales target, which strengthened the growth outlook.
+Should I buy GKOS stock now?
The earnings update is strong, but the stock has already moved sharply higher, so chasing it immediately carries risk. A more disciplined approach is to wait for regular-session confirmation and see whether the breakout holds above prior resistance levels.
+Did Glaukos beat earnings expectations in Q3?
Yes. Glaukos reported adjusted Q3 earnings of $0.47 per share versus a consensus estimate for a $0.12 loss. Revenue also came in well above expectations.
+What is the biggest catalyst for GKOS right now?
The biggest catalyst is the combination of record revenue, expanding gross margins and higher forward guidance. The preliminary 2027 sales target of $1 billion is especially important because it suggests the company sees a much larger long-term market opportunity.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on GKOS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.